| |
 |
|
|
Science Forum Index » Medicine - Nutrition Forum » DHA effective at lowering triglycerides in patients
Page 1 of 1
|
| Author |
Message |
| Ron Peterson |
 Posted: Tue Feb 06, 2007 12:19 pm |
|
|
|
Guest
|
See http://www.jacn.org/cgi/content/abstract/25/6/480
Abstract:
The Triglyceride-Lowering Effects of a Modest Dose of Docosahexaenoic
Acid Alone Versus in Combination with Low Dose Eicosapentaenoic Acid
in Patients with Coronary Artery Disease and Elevated Triglycerides
Lisa J. Schwellenbach, PharmD, BCPS, Kari L. Olson, PharmD, BCPS,
Karen J. McConnell, PharmD, BCPS, Ryan S. Stolcpart, PharmD, BCPS,
James D. Nash, Pharm D, BCPS, John A. Merenich, MD, FACP for the
Clinical Pharmacy Cardiac Risk Service Study Group
Kaiser Permanente Colorado, School of Pharmacy at Denver
Health Sciences Center
Colorado Permanente Medical Group
University of Colorado Health Sciences Center, Denver, Colorado
Clinical Advisor-Clinical Pharmacy Programs, Humana Inc., Louisville,
Kentucky
Address reprint requests to: Kari L. Olson, PharmD, BCPS, Kaiser
Permanente Colorado-Clinical Pharmacy Cardiac Risk Service, 16601 East
Centretech Parkway, Aurora, CO 80011. E-mail: kari.olson@kp.org
Background: Hypertriglyceridemia is a risk factor for coronary artery
disease (CAD). The American Heart Association recommends 1000 mg of
omega-3 fatty acids, docosahexaenoic acid (DHA) and eicosapentaenoic
acid (EPA), daily for cardioprotection and higher doses for
triglyceride-lowering in patients with CAD.
Methods: This was a prospective, randomized, double-blind study
comparing DHA to DHA + EPA in patients with CAD and triglycerides
greater than 200 mg/dL. Subjects were randomized to either 1000 mg of
DHA or 1252 mg of DHA + EPA for eight weeks. Baseline and eight-week
laboratories were drawn to assess changes in the fasting lipid
profile. The primary objective was to evaluate the change in
triglycerides between the two groups at eight weeks.
Results: A total of 116 subjects were enrolled; 57 in the DHA group
and 59 in the DHA + EPA group. Baseline characteristics were similar
between groups. The mean age was 69.4 ± 9.1 years and 70.7% were male.
Triglycerides decreased by an average of 21.8% in the DHA group (p <
0.001) and 18.3% in the DHA + EPA group (p < 0.001). The difference
between groups was not significant. A greater proportion of subjects
in the DHA group achieved triglyceride goal (less than 150 mg/dL)
compared to the DHA + EPA group (24.6% versus 10.2%, p < 0.05).
Conclusions: Our results indicate that the American Heart Association
recommended cardioprotective dose of omega-3 fatty acids can also
significantly lower triglycerides in patients with CAD. There do not
appear to be significant differences in triglyceride-lowering between
DHA only and DHA + EPA combination products when dosing is based on
DHA.
Key words: coronary artery disease, hypertriglyceridemia, omega-3
fatty acids
--
Ron |
|
|
| Back to top |
|
| |
|
Page 1 of 1
All times are GMT - 5 Hours
The time now is Fri Dec 05, 2008 12:42 pm
|
|